Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.

Toshiki KijimaHina YamamotoKazutaka SaitoShota KusuharaSoichiro YoshidaMinato YokoyamaYoh MatsuokaNoboru NumaoYasuyuki SakaiNobuaki MatsubaraTakeshi YuasaHitoshi MasudaJunji YoneseYukio KageyamaYasuhisa Fujii

Published in: Cancer immunology, immunotherapy : CII (2020)

Early CRP kinetics is associated with survival of advanced urothelial cancer patients treated with pembrolizumab and could be a potential biomarker for clinical benefit from immune checkpoint inhibitors.

Keyphrases

papillary thyroid
squamous cell
high grade
advanced non small cell lung cancer
free survival
lymph node metastasis
childhood cancer
young adults
aqueous solution
epidermal growth factor receptor